
Paul Stoffels, chief scientific officer at Johnson & Johnson, will exit his role at the company effective from the end of 2021, reports Bloomberg News.
The pharmaceutical giant has yet to find a replacement for Paul Stoffels, who has been with the company since 2002, spearheading the development of many treatments for HIV, Ebola and Zika virus, for example.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app